Clinical-stage pharmaceutical Incannex Healthcare Ltd. (Nasdaq: IXHL) is moving forward with a new psychotherapy treatment program using psilocybin, the company announced Thursday. The Melbourne, Australia-based firm will ask the U.S. Food and Drug Administration for the green light to begin clinical trials in the U.S. for its Psi-GAD therapy. Its …
Category: Psychedelics
Braxia Scientific’s Financial Struggles Overshadow Treatment Successes
Braxia Scientific Corp. (CSE: BRAX) saw its ketamine treatments rise by 26% and revenue increase by 27% over the year ending March 31, 2023, but financial statements indicate that the company’s ability to continue its operations could be in jeopardy. Braxia, which recently completed dosing in its phase 2 psilocybin …
Red Light Holland Sees Rising Revenue, Better Margins in 2023
Ontario-based mushroom maker Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) reported a decent boost in both revenue and gross profit for its fiscal year ending March 31, 2023. The company, known for its premium brand of psilocybin truffles sold in the Netherlands’ legal, recreational market, saw its revenue rise …